9 Jun 2015 14:00
C4X Discovery Holdings plc ("C4XD" or "the Company")
Grant of Options
C4X Discovery Holdings plc (AIM: C4XD), a leader in rational drug discovery and design, announces, as part of its remuneration policy to attract and retain key employees, the grant of options over 290,000 ordinary shares to directors and senior management ("Options").
The Options have an exercise price of 100p per share, being a premium of 19 per cent. to the current middle market price of a C4XD ordinary share, and can be exercised at any time between 3 years and 10 years of them being granted (8 June 2018 to 8 June 2025). There are no performance criteriaattached to the Options.
210,000 Options have been granted to senior employees with the balance being granted to directors as follows:
Director | Number of Options being granted | Total number of Options granted |
Clive Dix | 20,000 | 20,000 |
Harry Finch | 20,000 | 20,000 |
Piers Morgan | 20,000 | 20,000 |
Sam Williams | 20,000 | 20,000 |
Following the grant of these Options, the directors have the following interest in ordinary shares in the Company:
Director | Number of ordinary shares held | Total number of options over ordinary shares |
Clive Dix | 697,675 | 20,000 |
Harry Finch | 321,425 | 20,000 |
Piers Morgan | 30,000 | 880,000 |
Sam Williams | 1,069,625 | 20,000 |
For further information please contact:
C4X Discovery Holdings plc
Piers Morgan, CEO 07912 293832
Zeus Capital
Ross Andrews/Dan Bate 0161 831 1512
Dominic Wilson 020 7533 7727
FTI Consulting
Matthew Cole / Ben Atwell / Matthew Moss, 020 3727 1000
About C4XD
C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com